Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $13

Benzinga Newsdesk www.benzinga.com Positive 78.8%

Neg 0% Neu 0% Pos 78.8%

Chardan Capital analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $11 to $13.